New - STD pathogens molecular testing reageants
Ended Definitive Contract Awarded Last action
- Contract number
- W91YTZ21C0012
- Awardee
-
Cepheid UEI W6HQTMWB9Q28
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $2,398,990
Award facts
- Opportunity
-
- STD Pathogens Molecular Testing Reagents Pre-Solicitation · W91YTZ21Q0105 · Posted Apr 30, 2021
- Contract value 78% obligated
- $3,064,453.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Liberty, NC 28310, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | -$141,397 | |
| Exercise an Option | $0 | |
| Funding Only Action | $665,147 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $45,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $710,217 | |
| Exercise an Option | $0 | |
| Terminate for Convenience | -$342,811 | |
| Funding Only Action | $710,217 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Funding Only Action | $752,617 | |
| Original award | $0 |
Show all 18
About this award
The Defense Health Agency awarded Cepheid Inc. a $3.06 million firm fixed-price definitive contract on October 1, 2021, for the supply of standard pathogen molecular testing reagents. The contract, which runs through September 30, 2026, supports diagnostic testing operations at Fort Liberty, North Carolina (formerly Fort Bragg), specifically servicing the Pathology Department at Womack Army Medical Center. The procurement originated from a pre-solicitation notice posted in April 2021 that sought FDA-approved molecular testing reagents compatible with the Cepheid GeneXpert diagnostic platform for detecting methicillin-resistant Staphylococcus aureus, Group A Streptococcus, Group B Streptococcus, and other standard pathogens. No set-aside designation was used for this award.
Cepheid, a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems and reagents, represents a primary federal supplier of infectious disease diagnostic solutions across the Department of Defense and other federal healthcare agencies. The company's extensive federal contract portfolio includes significant indefinite delivery contracts with the Department of Veterans Affairs valued at over $39 million and multiple delivery orders from the Defense Health Agency, Defense Logistics Agency, and Indian Health Service. This definitive contract award reflects the company's established capability as a sole-source supplier of GeneXpert-compatible molecular testing reagents to support military medical center laboratory operations.
Quick answers
Who was awarded contract W91YTZ21C0012?
W91YTZ21C0012 was awarded to Cepheid by Medical Command (Department of the Army) on October 1, 2021.
How much is contract W91YTZ21C0012 worth?
The government has obligated $2,398,990 on W91YTZ21C0012. Its current value, with exercised options, is $3,064,454.
Which agency awarded contract W91YTZ21C0012?
Medical Command (Department of the Army) awarded W91YTZ21C0012, with funding from Defense Health Agency (Department of Defense).
Was contract W91YTZ21C0012 competed?
The extent of competition for W91YTZ21C0012 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award